Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The Health Secretary said the jabs were not the only solution to obesity but said they would help increase employment ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...
Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...